New stock news | CanSino Biologics submits application to Hong Kong Stock Exchange

According to the finance and economics app of China Securities, it was disclosed by the Hong Kong Stock Exchange on November 6 that Cansino Biologics Inc. (referred to as Cansino Biologics) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CICC International as its exclusive sponsor. The prospectus reveals that Cansino Biologics is an innovative, internationally-oriented biopharmaceutical company, focusing on the research and development, production, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies. The company is one of the earliest established biopharmaceutical companies in China and is one of the first industrialization bases of the national "863" plan.